201144317- 324.Avena NM Bocarsly ME Dysregulation of brain reward systems in eating disorders neurochemical information from animal models of binge eating bulimia nervosa and anorexia nervosa.

Eating attitudes of anorexia nervosa bulimia nervosa binge eating dis o rder and obe sity without eating disorder female patient s differences and simi laritie s. Physiol Behav .

The approval was based on three studies which found LDX superior to pla cebo for reducing binge eating days obsessive-compulsive binge eating symptom s and body weight and for inducing 4- week binge eating cessation rates 145- 147.

The potenti al indicati on is given in bracket s. Abbr eviati ons Anorexia nervosa AN bulimia nervosa BN binge eating di sorder BED opi oid s Op cann abin oid s CB dopamin e DA se rot onin 5-HT norepin ephrin e NE acetylch olin e ACh glut am at e Glu  n europeptid e Y NPY agouti -related peptid e AgRP melanocyte-stimulating hormone a-MSH cocain e and amph etamin e regul ated transcript CART glucagon-lik e peptid e-1 GLP-1.

See discussions stats and author profiles for this publication at Article in Expert Review of Clinical Pharmacology  September 2017DOI 10.108017512433.2018.1383895CITATION1READS1822 authors including 210 PUBLICATIONS 2896 CITATIONS Some of the authors of this publication are also working on these related projectsprediction of antidepressive treatment Expert Review of Clinical PharmacologyISSN 1751-2433 Print 1751-2441 OnlineJournal homepage Psychopharmacological advances in eating disordersHubertus Himmerich Janet TreasureTo cite this article Hubertus Himmerich  Janet Treasure 2017 Psychopharmacological advances in eating disorders Expert Review of Clinical Pharmacology DOI 10.108017512433.2018.1383895To link to this article Accepted author version posted online 21 Sep 2017.

Published online 05 Oct 2017.Submit your article to this journalArticle views 27View related articlesView Crossmark dataFull Terms  Conditions of access and use can be found athtt p.actionjournaIlnformationjournaICodeierj20EXPERT REVIEW OF CLINICAL PHARMACOLOGY 2018https doi.org10.108017512433.2018.1383895REVIEWPsychopharmacological advances in eating disordersHubertus Himmerich and Janet TreasureDepartment of Psychological Medicine King's College London London UKTaylor  FrancisTaylor FrancisG roupr--0N......00u00.....'deg.....0ARTICLE HISTORYReceived 28 February 2017Accepted 20 September 2017KEYWORDSAn orexia nerv osa bulimia nervo sa binge eatin g disorder antipsychotics antidepressants olanzapine fluoxetine topiramat e lisdexamfetamine'20Oi0-..l0l0u..0OO Cl 02S0QIntroductionHistorical preliminary remarksDespite decades of clinical experience and research in the field of eating disorders EDs the prognosis for patients with EDs is still poor.

For furth er detail s see text.intake disorder an eating disturbance manifested by a restric tive eating pattern with persistent failure to meet appropriate nutritional needs pica the consumption of nonfood and rumination disorder regurgitation and rechewing food 16.

BED is characterized by the intermit tent consumption of large quantities of food binge eating at least once a week for 3 months without the use of the extreme compensatory strategies such as purging used in BN 16.The spectrum of EDsGiven that transitions between diagnostic categories are com mon some theorists have proposed dimensional models of EDs or - in other words - a spectrum of disordered eating.

These divergent activation patterns may be respon sible for the inability of patients with BN to control conflicting desires to consume fattening foods on the one hand and toavoid weight gain on the other hand 51.Neural reward dysfunction in the hedonic system may underpin dysfunctional eating behavior in AN BN and BED with AN associated with too little striving for reward and binge eating too much 53- 62105 .

Patients with AN show less hedonic response to eating but consider behaviors like self-starvation- which are considered aversive and punishing in healthy people - more rewarding than eating 106.

